Equity Brief · Healthcare2026-10-27
PMED.MI·Healthcare

PiùMedical S.p.A.

I · AI Analysis

The brief

PiùMedical operates retail pharmacies in Lombardy, Italy, selling pharmaceuticals, supplements, cosmetics, and medical devices [Yahoo Finance]. The company also provides in-store health services such as diagnostic tests (ECG, blood work, sleep monitoring), consultations (nutritionist, oncology), and wellness treatments (massage, aromatherapy, yoga) [Yahoo Finance]. It employs 88 people and runs a consolidation platform with a buy-fix-scale model to expand in the retail pharmacy sector [Yahoo Finance].

PiùMedical S.p.A. operates a chain of retail pharmacies in Lombardy, Italy, selling prescription and over-the-counter medications, supplements, cosmetics, and medical devices under the 'Più Medical' brand [Yahoo Finance]. The company also offers in-store health services including diagnostic testing, consultations, and wellness treatments [Yahoo Finance]. Recent news reports profit increased fivefold and revenue grew 31% [Milano Finanza], though this conflicts with the trailing twelve months through 30 June 2026 showing revenue of EUR 6.9M with only 2.2% growth in the latest reported period [Yahoo Finance].

A small-cap pharmacy chain showing negative trailing net income but a forward estimate suggesting recovery, with low liquidity and significant structural risk [Yahoo Finance] [Sentinellis calculation].

The brief AI analysisConfidence 4/10

Sentinellis health

Significant risks

3.9/10

7.5+ strong · 4.5–7.5 moderate · under 4.5 weak

Profitability

21% of score0.0/10
Net margin-0.2%· need ≥ 6.9%, the lower third of Healthcare in our libraryGross margin+39.8%· need ≥ 57.4%, the lower third of Healthcare in our library

Returns on capital

21% of score0.0/10
ROIC+9.0%· need > 10%Return on equity-0.1%· need > 12%

Growth & momentum

14% of score0.0/10
Revenue growth+2.2%· need ≥ 2.9%, the lower third of Healthcare in our libraryOperating margin trend—· no data

Balance sheet

43% of score9.2/10
Current ratio3.0xNet debt / EBITDA-14.5xInterest coverage3.4x· need > 6.0xDebt / equity0.35

Cash generation

no data
Free cash flow—· no dataCash vs reported profit—· no data

Value creation

no data
ROIC vs cost of capital—· no data

Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.

Market capitalisation

EUR 37.7M

Revenue (TTM)

EUR 6.9M

Explainers

How we read these numbers

Plain-English guides · no account needed

II · Recent news

What moved

1 story · ranked by relevance

  • Company2026-09-30

    Più Medical, utile quintuplicato e ricavi in crescita del 31% - Milano Finanza

    Milano Finanza

Premium · Free with any account

The trailing twelve-month net margin is -0.2%, meaning the company posted a small net loss through 30 June 2026, and free cash flow data is unavailable [Yahoo Finance].

1 of 6 risks in this report

Risks

6

Opportunities

5

Red flags

4

Leadership

2

14 more findings in the full report — free with any account.

Unlock the full PiùMedical S.p.A. analysis

Create a free account to access the complete AI-generated report with inline citations.

  • 6 risks, 5 opportunities and 4 red flags — each with its source
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Unlock all 15 findings3 free reports · No credit card

III · Related

You might also read

Same sector · Healthcare — or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports

Produced 27 Oct 2026, 11:03 UTC

Figures come from company filings and market data. The Sentinellis health score and the wording attached to it are our interpretation of those figures, not numbers the company reported.

Not investment advice and not a recommendation to buy or sell. Sentinellis holds no positions in the companies it covers, takes no payment from issuers, and has no broker referral arrangements.

How every figure and score is calculated